[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506685":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":32,"locations":38,"responsibleParty":200,"collaborators":28,"id":202,"slug":28,"hasResults":203,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":28,"eligibilityCriteria":207,"healthyVolunteers":203,"sex":208,"minAge":209,"maxAge":28,"enrollmentInfo":210,"targetDuration":28,"studyType":213,"phases":214,"briefSummary":216,"conditions":217,"keywords":225,"overallStatus":41,"whyStopped":28,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation and Expansion","EXPERIMENTAL","Dose Escalation of TCR T cell product",[13],"Biological: Autologous, engineered T Cells targeting TP53 R175H",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 1: Disease Histology Evaluation","TCR T Cell Product at the MTD",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part 2: Disease Cohort Expansion","TCR T Cell Product at the RP2D",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","Autologous, engineered T Cells targeting TP53 R175H","* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide\n* Single infusion TCR T cells\n* Post-infusion recombinant interleukin-2 (rIL-2)",[9,15,19],null,[30],{"name":5,"affiliation":5,"role":31},"STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":28,"email":37},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[39,53,62,70,78,87,96,104,113,122,130,139,147,156,165,174,183,191],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":28},"Research Site","RECRUITING","Gilbert","Arizona","85234","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-111.78903,33.35283,{"lat":51,"lon":50},{"facility":40,"status":41,"city":54,"state":55,"zip":56,"country":45,"countryCode":46,"cosmosGeoPoint":57,"geoPoint":61,"contacts":28},"Duarte","California","91010",{"type":48,"coordinates":58},[59,60],-117.97729,34.13945,{"lat":60,"lon":59},{"facility":40,"status":41,"city":63,"state":55,"zip":64,"country":45,"countryCode":46,"cosmosGeoPoint":65,"geoPoint":69,"contacts":28},"Newport Beach","92663",{"type":48,"coordinates":66},[67,68],-117.92895,33.61891,{"lat":68,"lon":67},{"facility":40,"status":41,"city":71,"state":55,"zip":72,"country":45,"countryCode":46,"cosmosGeoPoint":73,"geoPoint":77,"contacts":28},"Santa Monica","90404",{"type":48,"coordinates":74},[75,76],-118.49138,34.01949,{"lat":76,"lon":75},{"facility":40,"status":41,"city":79,"state":80,"zip":81,"country":45,"countryCode":46,"cosmosGeoPoint":82,"geoPoint":86,"contacts":28},"Jacksonville","Florida","32224",{"type":48,"coordinates":83},[84,85],-81.65565,30.33218,{"lat":85,"lon":84},{"facility":40,"status":88,"city":89,"state":80,"zip":90,"country":45,"countryCode":46,"cosmosGeoPoint":91,"geoPoint":95,"contacts":28},"WITHDRAWN","Miami","33136",{"type":48,"coordinates":92},[93,94],-80.19366,25.77427,{"lat":94,"lon":93},{"facility":40,"status":88,"city":97,"state":80,"zip":98,"country":45,"countryCode":46,"cosmosGeoPoint":99,"geoPoint":103,"contacts":28},"Tampa","33612",{"type":48,"coordinates":100},[101,102],-82.45843,27.94752,{"lat":102,"lon":101},{"facility":40,"status":41,"city":105,"state":106,"zip":107,"country":45,"countryCode":46,"cosmosGeoPoint":108,"geoPoint":112,"contacts":28},"Boston","Massachusetts","02115",{"type":48,"coordinates":109},[110,111],-71.05977,42.35843,{"lat":111,"lon":110},{"facility":40,"status":41,"city":114,"state":115,"zip":116,"country":45,"countryCode":46,"cosmosGeoPoint":117,"geoPoint":121,"contacts":28},"New Brunswick","New Jersey","08901",{"type":48,"coordinates":118},[119,120],-74.45182,40.48622,{"lat":120,"lon":119},{"facility":40,"status":41,"city":123,"state":123,"zip":124,"country":45,"countryCode":46,"cosmosGeoPoint":125,"geoPoint":129,"contacts":28},"New York","10065",{"type":48,"coordinates":126},[127,128],-74.00597,40.71427,{"lat":128,"lon":127},{"facility":40,"status":88,"city":131,"state":132,"zip":133,"country":45,"countryCode":46,"cosmosGeoPoint":134,"geoPoint":138,"contacts":28},"Charlotte","North Carolina","28204",{"type":48,"coordinates":135},[136,137],-80.84313,35.22709,{"lat":137,"lon":136},{"facility":40,"status":88,"city":140,"state":132,"zip":141,"country":45,"countryCode":46,"cosmosGeoPoint":142,"geoPoint":146,"contacts":28},"Winston-Salem","27103",{"type":48,"coordinates":143},[144,145],-80.24422,36.09986,{"lat":145,"lon":144},{"facility":40,"status":41,"city":148,"state":149,"zip":150,"country":45,"countryCode":46,"cosmosGeoPoint":151,"geoPoint":155,"contacts":28},"Portland","Oregon","97213",{"type":48,"coordinates":152},[153,154],-122.67621,45.52345,{"lat":154,"lon":153},{"facility":40,"status":41,"city":157,"state":158,"zip":159,"country":45,"countryCode":46,"cosmosGeoPoint":160,"geoPoint":164,"contacts":28},"Pittsburgh","Pennsylvania","15232",{"type":48,"coordinates":161},[162,163],-79.99589,40.44062,{"lat":163,"lon":162},{"facility":40,"status":41,"city":166,"state":167,"zip":168,"country":45,"countryCode":46,"cosmosGeoPoint":169,"geoPoint":173,"contacts":28},"Nashville","Tennessee","37203",{"type":48,"coordinates":170},[171,172],-86.78444,36.16589,{"lat":172,"lon":171},{"facility":40,"status":41,"city":175,"state":176,"zip":177,"country":45,"countryCode":46,"cosmosGeoPoint":178,"geoPoint":182,"contacts":28},"Houston","Texas","77030",{"type":48,"coordinates":179},[180,181],-95.36327,29.76328,{"lat":181,"lon":180},{"facility":40,"status":41,"city":184,"state":176,"zip":185,"country":45,"countryCode":46,"cosmosGeoPoint":186,"geoPoint":190,"contacts":28},"Round Rock","78665",{"type":48,"coordinates":187},[188,189],-97.6789,30.50826,{"lat":189,"lon":188},{"facility":40,"status":41,"city":192,"state":193,"zip":194,"country":45,"countryCode":46,"cosmosGeoPoint":195,"geoPoint":199,"contacts":28},"Milwaukee","Wisconsin","53226",{"type":48,"coordinates":196},[197,198],-87.90647,43.0389,{"lat":198,"lon":197},{"type":201,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100506685",false,"NCT05877599","A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and\u002For Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and\u002For Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation","Key Inclusion Criteria\n\n* Subjects must be at least 18 years of age, at the time of signing the informed consent.\n* Subjects must be capable of giving signed informed consent.\n* Subject must be diagnosed with one of the histologies below:\n\n  * NSCLC\n  * Colorectal adenocarcinoma\n  * HNSCC\n  * Pancreatic adenocarcinoma\n  * Breast cancer\n  * Ovarian cancer\n  * Any other solid tumor\n* Tumors must harbor a TP53 R175H variant mutation and subject must be HLA-A\\*02:01 positive (at least 1 allele) as confirmed by an CLIA-accredited laboratory-based test.\n* Subject has advanced solid cancer, defined as unresectable, advanced, and\u002For metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options.\n* Subject has at least 1 measurable lesion per computed tomography (CT) scan or magnetic resonance imaging (MRI) per RECIST version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment\n* Adequate hematological, renal, hepatic, pulmonary, and cardiac function\n* Per Investigator judgement, subject is likely to complete study visits and\u002For procedures per the protocol and comply with study requirements for study participation\n\nKey Exclusion Criteria\n\n* Any another primary malignancy within the 3 years prior to enrollment (except for non-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or low-grade prostate cancer\n* Known, active primary central nervous system (CNS) malignancy\n* History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.\n* History of stroke or transient ischemic attack within the 12 months prior to enrollment.\n* History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.\n* Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or rIL-2; or known sensitivity or allergy to methotrexate, gentamicin, or other aminoglycosides.\n* Any form of primary immunodeficiency.\n* Live vaccine ≤ 4 weeks prior to enrollment or plans to have a live vaccine prior to planned lymphodepleting chemotherapy and\u002For NT-175 treatment.\n* Active immune-mediated disease requiring systemic steroids or other immunosuppressive treatment (except if related to prior checkpoint inhibitor therapy)\n* Female of childbearing potential who is lactating or breast feeding at the time of enrollment.\n* Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.","ALL","18 Years",{"count":211,"type":212},45,"ESTIMATED","INTERVENTIONAL",[215],"PHASE1","Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.",[218,219,220,221,222,223,224],"Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Carcinoma","Pancreatic Adenocarcinoma","Breast Cancer","Other Solid Tumors","Ovarian Cancer",[226,227,228,229,230,231,232,222,224,233],"Cell therapy","TP53","Solid tumors","Non-small cell lung cancer","Head and neck squamous cell carcinoma","Colorectal carcinoma","Pancreatic adenocarcinoma","TCR","2026-06-09",{"date":236,"type":237},"2026-06-10","ACTUAL",{"date":239,"type":237},"2023-07-12",{"date":241,"type":212},"2029-07-31",{"name":5,"class":6},18]